A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink
Cristina Rebordosa, 1 Estel Plana, 1 Annalisa Rubino, 2 Jaume Aguado, 1 Alejhandra Lei, 3 Sami Daoud, 4 Nuria Saigi-Morgui, 1 Susana Perez-Gutthann, 1 Elena Rivero-Ferrer 1 1RTI Health Solutions, Barcelona, Spain; 2Epidemiology, Respiratory and Immunology, AstraZeneca, Cambridge, UK; 3Patient Safety...
Published in: | International Journal of Chronic Obstructive Pulmonary Disease |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Dove Press
2021
|
Subjects: | |
Online Access: | https://www.dovepress.com/a-cohort-study-to-evaluate-the-risk-of-hospitalisation-for-congestive--peer-reviewed-fulltext-article-COPD |
id |
ftdovepress:oai:dovepress.com/65320 |
---|---|
record_format |
openpolar |
spelling |
ftdovepress:oai:dovepress.com/65320 2023-05-15T18:13:18+02:00 A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink Rebordosa,Cristina Plana,Estel Rubino,Annalisa Aguado,Jaume Lei,Alejhandra Daoud,Sami Saigi-Morgui,Nuria Perez-Gutthann,Susana Rivero-Ferrer,Elena 2021-05-31 text/html https://www.dovepress.com/a-cohort-study-to-evaluate-the-risk-of-hospitalisation-for-congestive--peer-reviewed-fulltext-article-COPD en eng Dove Press info:eu-repo/semantics/altIdentifier/doi/10.2147/COPD.S301624 https://www.dovepress.com/a-cohort-study-to-evaluate-the-risk-of-hospitalisation-for-congestive--peer-reviewed-fulltext-article-COPD info:eu-repo/semantics/openAccess International Journal of Chronic Obstructive Pulmonary Disease Original Research info:eu-repo/semantics/article 2021 ftdovepress https://doi.org/10.2147/COPD.S301624 2022-12-27T23:12:05Z Cristina Rebordosa, 1 Estel Plana, 1 Annalisa Rubino, 2 Jaume Aguado, 1 Alejhandra Lei, 3 Sami Daoud, 4 Nuria Saigi-Morgui, 1 Susana Perez-Gutthann, 1 Elena Rivero-Ferrer 1 1RTI Health Solutions, Barcelona, Spain; 2Epidemiology, Respiratory and Immunology, AstraZeneca, Cambridge, UK; 3Patient Safety Biopharma, AstraZeneca, Barcelona, Spain; 4BioPharmaceuticals Research and Development, Late-Stage Development Research and Innovation, AstraZeneca, Gaithersburg, MD, USACorrespondence: Cristina RebordosaRTI Health Solutions, Av. Diagonal, 605, 9-1, Barcelona, 08028, SpainTel +34 93 241 7766Fax +34 93 760 8507Email crebordosa@rti.orgBackground: The long-acting anticholinergic (LAMA) aclidinium was approved in Europe in 2012 to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD). A Post-Authorisation Safety Study (PASS) was initiated to assess potential cardiovascular safety concerns for aclidinium.Objective: To estimate the adjusted incidence rate ratio (IRR) for hospitalisation for heart failure in patients with COPD who were new users of aclidinium, tiotropium, other LAMA, long-acting beta-agonists/inhaled corticosteroids (LABA/ICS), and LAMA/LABA were compared with initiators of LABA.Methods: This population-based cohort study included patients with COPD aged ≥ 40 years initiating COPD medications in the Clinical Practice Research Datalink (CPRD) GOLD in the United Kingdom from 2012 to 2017. Medications were identified via general practice prescriptions. The first-ever hospitalisations for heart failure were identified in the Hospital Episode Statistics, and general practitioner records from the CPRD. Poisson regression models were used to estimate the IRR for hospitalisation for heart failure in users of COPD medications versus LABA, adjusting for clinically relevant covariates.Results: The study included 4350 new users of aclidinium, 23,405 of tiotropium, 6977 of other LAMAs, 3122 of LAMA/LABA, 26,093 of LABA/ICS, and 5678 of LABA. Mean age was 69– 70 years across medication groups. ... Article in Journal/Newspaper sami Dove Medical Press Ferrer ENVELOPE(-63.883,-63.883,-64.700,-64.700) Jaume ENVELOPE(-63.750,-63.750,-65.483,-65.483) Lamas ENVELOPE(-56.933,-56.933,-64.333,-64.333) Perez ENVELOPE(-69.117,-69.117,-68.517,-68.517) Rivero ENVELOPE(-62.033,-62.033,-64.550,-64.550) International Journal of Chronic Obstructive Pulmonary Disease Volume 16 1461 1475 |
institution |
Open Polar |
collection |
Dove Medical Press |
op_collection_id |
ftdovepress |
language |
English |
topic |
International Journal of Chronic Obstructive Pulmonary Disease |
spellingShingle |
International Journal of Chronic Obstructive Pulmonary Disease Rebordosa,Cristina Plana,Estel Rubino,Annalisa Aguado,Jaume Lei,Alejhandra Daoud,Sami Saigi-Morgui,Nuria Perez-Gutthann,Susana Rivero-Ferrer,Elena A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink |
topic_facet |
International Journal of Chronic Obstructive Pulmonary Disease |
description |
Cristina Rebordosa, 1 Estel Plana, 1 Annalisa Rubino, 2 Jaume Aguado, 1 Alejhandra Lei, 3 Sami Daoud, 4 Nuria Saigi-Morgui, 1 Susana Perez-Gutthann, 1 Elena Rivero-Ferrer 1 1RTI Health Solutions, Barcelona, Spain; 2Epidemiology, Respiratory and Immunology, AstraZeneca, Cambridge, UK; 3Patient Safety Biopharma, AstraZeneca, Barcelona, Spain; 4BioPharmaceuticals Research and Development, Late-Stage Development Research and Innovation, AstraZeneca, Gaithersburg, MD, USACorrespondence: Cristina RebordosaRTI Health Solutions, Av. Diagonal, 605, 9-1, Barcelona, 08028, SpainTel +34 93 241 7766Fax +34 93 760 8507Email crebordosa@rti.orgBackground: The long-acting anticholinergic (LAMA) aclidinium was approved in Europe in 2012 to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD). A Post-Authorisation Safety Study (PASS) was initiated to assess potential cardiovascular safety concerns for aclidinium.Objective: To estimate the adjusted incidence rate ratio (IRR) for hospitalisation for heart failure in patients with COPD who were new users of aclidinium, tiotropium, other LAMA, long-acting beta-agonists/inhaled corticosteroids (LABA/ICS), and LAMA/LABA were compared with initiators of LABA.Methods: This population-based cohort study included patients with COPD aged ≥ 40 years initiating COPD medications in the Clinical Practice Research Datalink (CPRD) GOLD in the United Kingdom from 2012 to 2017. Medications were identified via general practice prescriptions. The first-ever hospitalisations for heart failure were identified in the Hospital Episode Statistics, and general practitioner records from the CPRD. Poisson regression models were used to estimate the IRR for hospitalisation for heart failure in users of COPD medications versus LABA, adjusting for clinically relevant covariates.Results: The study included 4350 new users of aclidinium, 23,405 of tiotropium, 6977 of other LAMAs, 3122 of LAMA/LABA, 26,093 of LABA/ICS, and 5678 of LABA. Mean age was 69– 70 years across medication groups. ... |
format |
Article in Journal/Newspaper |
author |
Rebordosa,Cristina Plana,Estel Rubino,Annalisa Aguado,Jaume Lei,Alejhandra Daoud,Sami Saigi-Morgui,Nuria Perez-Gutthann,Susana Rivero-Ferrer,Elena |
author_facet |
Rebordosa,Cristina Plana,Estel Rubino,Annalisa Aguado,Jaume Lei,Alejhandra Daoud,Sami Saigi-Morgui,Nuria Perez-Gutthann,Susana Rivero-Ferrer,Elena |
author_sort |
Rebordosa,Cristina |
title |
A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink |
title_short |
A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink |
title_full |
A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink |
title_fullStr |
A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink |
title_full_unstemmed |
A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink |
title_sort |
cohort study to evaluate the risk of hospitalisation for congestive heart failure associated with the use of aclidinium and other chronic obstructive pulmonary disease medications in the uk clinical practice research datalink |
publisher |
Dove Press |
publishDate |
2021 |
url |
https://www.dovepress.com/a-cohort-study-to-evaluate-the-risk-of-hospitalisation-for-congestive--peer-reviewed-fulltext-article-COPD |
long_lat |
ENVELOPE(-63.883,-63.883,-64.700,-64.700) ENVELOPE(-63.750,-63.750,-65.483,-65.483) ENVELOPE(-56.933,-56.933,-64.333,-64.333) ENVELOPE(-69.117,-69.117,-68.517,-68.517) ENVELOPE(-62.033,-62.033,-64.550,-64.550) |
geographic |
Ferrer Jaume Lamas Perez Rivero |
geographic_facet |
Ferrer Jaume Lamas Perez Rivero |
genre |
sami |
genre_facet |
sami |
op_relation |
info:eu-repo/semantics/altIdentifier/doi/10.2147/COPD.S301624 https://www.dovepress.com/a-cohort-study-to-evaluate-the-risk-of-hospitalisation-for-congestive--peer-reviewed-fulltext-article-COPD |
op_rights |
info:eu-repo/semantics/openAccess |
op_doi |
https://doi.org/10.2147/COPD.S301624 |
container_title |
International Journal of Chronic Obstructive Pulmonary Disease |
container_volume |
Volume 16 |
container_start_page |
1461 |
op_container_end_page |
1475 |
_version_ |
1766185814721560576 |